MedSina
Health library › Evidence-based

PFO Closure for Stroke Prevention: Evidence and Patient Selection

October 23, 2026·5 min read ·MedSina Evidence · PubMed

Transcatheter closure of a patent foramen ovale (PFO) has emerged as an effective strategy for preventing recurrent cryptogenic strokes in carefully selected patients, supported by recent clinical trial evidence.

PFO Closure for Stroke Prevention: Evidence and Patient Selection

A patent foramen ovale (PFO) is a common heart condition that has been a significant area of research and discussion regarding its role in stroke prevention. While many people live with a PFO without issues, for some, it can be linked to a type of stroke known as cryptogenic stroke, meaning its cause is unknown [2, 5, 8]. Recent advancements in medical understanding and technology have led to a clearer picture of when and for whom PFO closure can be a beneficial strategy for preventing future strokes [1, 2, 4].

Understanding a Patent Foramen Ovale (PFO)

The foramen ovale is a natural opening between the upper two chambers of the heart (the atria) that is present in everyone before birth. It allows blood to bypass the lungs, which are not yet functional in the womb [1]. Normally, this opening closes shortly after birth, typically within the first few months of life [1]. However, in about 25% of the general population, this flap-like opening does not fully seal, remaining 'patent' or open [2, 5]. This persistence of the foramen ovale is what is called a patent foramen ovale, or PFO [1].

PFO and Cryptogenic Stroke

For decades, the potential link between a PFO and ischemic stroke, particularly cryptogenic stroke, has been a subject of extensive investigation [2, 5, 8]. The primary concern is the possibility of a 'paradoxical embolism,' where a blood clot formed in the veins (e.g., in the legs) travels to the right side of the heart, passes through the PFO into the left side, and then travels to the brain, causing a stroke [2]. Because the PFO is so common, determining if it was truly the cause of a stroke, rather than just an incidental finding, has been challenging [2].

The Role of PFO Closure in Stroke Prevention

After years of debate, the evidence has increasingly supported transcatheter PFO closure for secondary stroke prevention in carefully selected patients [2, 4]. This procedure involves inserting a catheter, usually through a vein in the leg, to deliver a small device that seals the PFO, preventing blood from crossing between the heart chambers [1].

Multiple randomized controlled trials have demonstrated the benefit of PFO closure over medical therapy alone for reducing the risk of recurrent stroke in specific patient groups [1, 3, 4, 5, 6]. Long-term follow-up data from trials like RESPECT have shown evidence favoring PFO closure [4]. This robust evidence has led to regulatory approvals for PFO closure devices, such as the AMPLATZER™ and GORE™ septal occluders, for use in patients aged 18 to 60 years with a PFO and no other determined cause for their ischemic stroke [4]. Studies indicate that PFO closure is associated with a significant reduction in stroke risk, with the treatment effect remaining consistent over several years of follow-up [6].

Who Benefits from PFO Closure? Patient Selection is Key

The success and benefit of PFO closure for stroke prevention depend critically on careful patient selection [2, 5, 7, 8]. Not everyone with a PFO who has had a stroke will benefit from closure. Current evidence suggests that the greatest benefit is seen in patients who meet specific criteria:

A comprehensive diagnostic workup is essential to ensure that the PFO is indeed the most probable cause of the stroke before considering closure [2].

Potential Considerations and Future Research

While PFO closure is effective for selected patients, it is important to consider potential risks and areas where more research is needed. One known short-term risk associated with the closure procedure is the development of atrial fibrillation, an irregular heart rhythm [7]. Additionally, if a small residual shunt (an incomplete seal) remains after closure, it may predict a higher risk of stroke recurrence [7].

Several questions remain open in the field of PFO closure [1, 5, 8]. The benefit of closure in older patients (over 60) is still uncertain [5, 8]. The long-term risks associated with the closure devices and the procedure are not fully known [5]. Furthermore, the comparative efficacy of direct oral anticoagulants (DOACs) versus other medical therapies or PFO closure in this patient population is an ongoing area of study [5, 7]. Future research also aims to better understand the long-term consequences of post-closure atrial fibrillation and to ensure the generalizability of trial results to real-world clinical practice [8]. Patients should always discuss their individual circumstances and treatment options with their healthcare provider.

Sources

patent foramen ovalePFO closurestroke preventioncryptogenic strokeheart health

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.